Phase 2 RCT: Efficacy and safety of Deucravacitinib, a selective TYK2 inhibitor, in psoriatic arthritis.

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis – Annals of Rheumatic Diseases

Commentary on Twitter

https://twitter.com/ARD_BMJ/status/1499542657693097985